Autoimmune diseases are a class of diseases wherein the immune system of the body targets itself through autoreactive T cells and autoantibodies. Autoimmune diseases are classified as organ-specific autoimmune diseases and systemic autoimmune diseases. Organ-specific autoimmune diseases such as primary biliary cirrhosis, Hashimoto's Thyroiditis (HT), Type 1 Diabetes mellitus (T1D), and Graves' Disease (GD) are characterized by a unique immune system response to autoantigens in a single organ. Systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjogren syndrome are characterized by a systemic spread of autoantigens causing a multi-organ attack. In this review, we discuss rheumatoid arthritis, its prevalence in India, and its risk factors. We discuss the pharmacotherapies for RA that are currently available on the market. By identifying the disadvantages and side effects of the treatment, we mainly focus on how nanotechnology will be helpful in vaccine research and the advancement of anti-RA therapeutics from vaccines to nano-vaccines. In addition, the benefits of nano-vaccines are explored in future perspectives. In conclusion, nano-vaccines will be a novel technique for treating RA because they show possible outcomes from nanovaccine use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0115733971330575250121054355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Literature review of occurrence, effectiveness, safety, and hospitalization burden of blood transfusion in the management of warm autoimmune hemolytic anemia.
Hematology
December 2025
Department of Medicine, University of Washington, Seattle, WA, United States.
Introduction: Cases of warm autoimmune hemolytic anemia (wAIHA) often present with life-threatening levels of hemoglobin requiring red blood cell (RBC) transfusion support.
Aim: This literature review assessed the occurrence, safety, effectiveness, and hospitalization burden of RBC transfusions in the management of patients with wAIHA.
Methods: Electronic databases (Embase, MEDLINE) were searched from inception to December 2021 along with additional searches conducted up to March 2024.
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes.
J Immunol
January 2025
Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity.
View Article and Find Full Text PDFSuppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion.
J Immunol
January 2025
Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Decoy receptor 3 (DcR3), a soluble receptor in the tumor necrosis factor receptor superfamily, regulates the functions of monocytes, macrophages, dendritic cells, and T cells. Previous studies have demonstrated that DcR3 suppresses B cell proliferation in vitro and ameliorates autoimmune diseases in animal models; however, whether and how DcR3 regulates antibody production is unclear. Using a DcR3 transgenic mouse model, we found that DcR3 impaired the T cell-dependent antigen-stimulated antibody response.
View Article and Find Full Text PDFGenetic or therapeutic disruption of the Reelin/Apoer2 signaling pathway improves inflammatory arthritis outcomes.
Proc Natl Acad Sci U S A
March 2025
Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9046.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation, pannus formation, and progressive joint destruction. The inflammatory milieu in RA drives endothelial cell activation and upregulation of adhesion molecules, thus facilitating leukocyte infiltration into the synovium. Reelin, a circulating glycoprotein previously implicated in endothelial activation and leukocyte recruitment in diseases such as atherosclerosis and multiple sclerosis, has emerged as a potential upstream regulator of these processes.
View Article and Find Full Text PDFErratum corrige: Stressful life events are associated with the diagnosis of systemic autoimmune rheumatic diseases among adults.
Clin Exp Rheumatol
March 2025
Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, and Research Triangle Park, NC, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!